Adaptive Biotechnologies Corporation
NASDAQ:ADPT
7.2 (USD) • At close January 3, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 170.276 | 185.308 | 154.344 | 98.382 | 85.071 | 55.663 | 38.448 |
| Cost of Revenue
| 75.553 | 57.909 | 49.301 | 22.53 | 22.274 | 19.668 | 15.68 |
| Gross Profit
| 94.723 | 127.399 | 105.043 | 75.852 | 62.797 | 35.995 | 22.768 |
| Gross Profit Ratio
| 0.556 | 0.687 | 0.681 | 0.771 | 0.738 | 0.647 | 0.592 |
| Reseach & Development Expenses
| 122.117 | 141.756 | 142.343 | 116.072 | 70.705 | 39.157 | 31.995 |
| General & Administrative Expenses
| 83.934 | 88.527 | 74.502 | 49.536 | 30.332 | 20.409 | 15.949 |
| Selling & Marketing Expenses
| 88.579 | 95.603 | 95.465 | 61.358 | 38.453 | 24.486 | 16.765 |
| SG&A
| 172.513 | 184.13 | 169.967 | 110.894 | 68.785 | 44.895 | 32.714 |
| Other Expenses
| 27.128 | 1.699 | 1.699 | 1.703 | 1.698 | 1.699 | 1.694 |
| Operating Expenses
| 321.758 | 327.585 | 314.009 | 228.669 | 141.188 | 85.751 | 66.403 |
| Operating Income
| -227.035 | -200.186 | -208.966 | -152.817 | -78.391 | -49.756 | -44.475 |
| Operating Income Ratio
| -1.333 | -1.08 | -1.354 | -1.553 | -0.921 | -0.894 | -1.157 |
| Total Other Income Expenses Net
| 1.731 | -0.182 | 1.668 | 6.59 | 9.785 | 3.309 | 1.644 |
| Income Before Tax
| -225.304 | -200.368 | -207.298 | -146.227 | -68.606 | -46.447 | -42.831 |
| Income Before Tax Ratio
| -1.323 | -1.081 | -1.343 | -1.486 | -0.806 | -0.834 | -1.114 |
| Income Tax Expense
| 0 | -57.904 | -1.687 | -6.59 | -9.785 | 3.309 | -0.804 |
| Net Income
| -225.25 | -142.464 | -205.611 | -139.637 | -58.821 | -46.447 | -42.831 |
| Net Income Ratio
| -1.323 | -0.769 | -1.332 | -1.419 | -0.691 | -0.834 | -1.114 |
| EPS
| -1.56 | -1 | -1.46 | -1.06 | -0.85 | -0.44 | -0.41 |
| EPS Diluted
| -1.56 | -1 | -1.46 | -1.06 | -0.85 | -0.44 | -0.41 |
| EBITDA
| -189.273 | -167.983 | -193.345 | -144.345 | -70.6 | -43.756 | -37.839 |
| EBITDA Ratio
| -1.112 | -1.049 | -1.343 | -1.536 | -0.902 | -0.786 | -0.962 |